Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 8 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Sintilimab in combination with pemetrexed and platinum chemotherapy for advanced or metastatic non-small cell lung cancer	Carboplatin (Paraplatin) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium) , Sintilimab (IBI 308; IBI 380; Tyvyt)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Pembrolizumab in combination with pemetrexed and cisplatin for previously untreated advanced malignant pleural mesothelioma	Cisplatin (Platinol) , Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Malignant pleural mesothelioma (MPM)	Lung and Respiratory Cancer	2021	View \| Download
Pembrolizumab in combination with lenvatinib, platinum chemotherapy, and pemetrexed for non-small cell lung cancer	Chemotherapy , Lenvatinib (Kisplyx; E7080; lenvatinib mesilate) , Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2021	View \| Download
Pembrolizumab in addition to platinumpemetrexed chemotherapy for metastatic EGRF mutant non-squamous non-small-cell lung cancer – second line	Pembrolizumab (Keytruda; MK-3475) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Pegargiminase in addition to pemetrexed and cisplatin for advanced malignant pleural mesothelioma – first line	Cisplatin (Platinol) , Pegargiminase (ADI-PEG 20) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Malignant pleural mesothelioma (MPM)	Lung and Respiratory Cancer	2018	View \| Download
Osimertinib + pemetrexed + carboplatin +/ cisplatin as a first line treatment for non-small cell lung cancer with EGFR mutation	Carboplatin (Paraplatin) , Cisplatin (Platinol) , Osimertinib (Tagrisso; AZD9291; osimertinib mesylate) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2023	View \| Download
Nintedanib in combination with Pemetrexed and Cisplatin for Unresectable Malignant Pleural Mesothelioma – first line	Cisplatin (Platinol) , Nintedanib (Vargatef; Ofev; nintedanib esilate) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Malignant pleural mesothelioma (MPM)	Lung and Respiratory Cancer	2018	View \| Download
Atezolizumab in addition to Carboplatin or Cisplatin and Pemetrexed for Stage IV non-squamous non-small cell lung cancer (NSCLC)	Atezolizumab (Tecentriq; MPDL3280A) , Carboplatin (Paraplatin) , Cisplatin (Platinol) , Pemetrexed (Alimta; pemetrexed ditromethamine dihydrate; pemetrexed ditrometamol; pemetrexed disodium)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2018	View \| Download

About

Devices, Diagnostics & Digital

About

Data Science & AI

Devices, Diagnostics & Digital

Insights (Public/Patient)

Medicines

Medicine Industry's Gateway to NICE

Support for Industry

Outputs & Publications